Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects

Abstract

Based on the health-economic evaluation, the authors recommend the continuation of the general recommendation of PCV7 according to the 3 + 1 schedule within the German Statutory Health Insurance.

A public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in Germany

“…However, based on available information, one important difference lies in the assumptions on resource utilization associated with NBPP. The German source applied in the current study [54] reported a relatively low rate, whereas the rate used in the study presented at ACIP appeared to be much higher, as seen in the number of inpatient/outpatient CAP cases avoided and the corresponding assumptions on vaccine effectiveness. Data sources were not detailed.…”

“…The price of PPV23 (Pneumovax ® II, single-dose pack; Sanofi Pasteur MSD) was €30.25 and the current unit price of PCV13 (Prevenar 13 ® , single-dose pack; Pfizer, Inc.) was assumed to remain stable following the launch of the vaccine in adults (€65.02) [109]. Costs of administration and treatment of pneumococcal disease were retrieved from German sources [110,111] or updated from previous German studies [54,55] and are detailed in Table 3.…”

“…As shown in Figure 4 and supplemenTary Administration of vaccine €6.95 [31] Meningitis €11,664 [54] Invasive pneumonia €8075 [54] NBPP: inpatient €5762 [54] NBPP: outpatient €78 [54] Proportion of NBPP patients hospitalized (by age band in years; %) …”

Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany

“…For the treatment of hearing loss due to pneumococcal meningitis, the annual costs were estimated from a German cost-effectiveness analysis of cochlear implants in children [70]. The treatment costs of other neurological sequelae were estimated based on the ratio between the costs of treating hearing loss and other neurological sequelae in the study by Claes et al [69]. A copayment of €7 was applied to treatment and vaccine Research Article administration costs based on the assumption that 30% of the patients were fully exempted from a copayment of €10 [115,116].…”

“…The treatment of pneumococcal diseases and vaccine administration costs were obtained from German sources [11,114] and a German cost-effectiveness analysis conducted by Claes et al [69]. For the treatment of hearing loss due to pneumococcal meningitis, the annual costs were estimated from a German cost-effectiveness analysis of cochlear implants in children [70].…”